Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Analysis of informed consent forms of patients undergoing cancer genetic testing in the era of next-generation sequencing
Avtorji:ID Kerševan, Tina (Avtor)
ID Kogovšek, Tina (Avtor)
ID Blatnik, Ana (Avtor)
ID Krajc, Mateja (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (1,29 MB)
MD5: 4B7A9287B2FFDE537FBDA4B59B06C96E
 
URL URL - Izvorni URL, za dostop obiščite https://hccpjournal.biomedcentral.com/articles/10.1186/s13053-025-00309-8
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo OI - Onkološki inštitut Ljubljana
Povzetek:The Department of Clinical Cancer Genetics at the Institute of Oncology Ljubljana offers genetic counselling and testing to cancer patients and their relatives. Before undergoing genetic testing, patients sign the informed consent form. In addition to giving consent for collection of biological material and genetic testing, patients decide about storage of biological material and participation in international databases. Furthermore, patients decide whether the information regarding their test results may be revealed to their blood relatives and whether they want to be informed about secondary findings. Methods Using the signed consent forms, we investigated the effect of selected factors on patients’ decisions. Using different statistical methods, we tried to determine the proportion of patients who opted for different items and the effect of gender, age and cancer diagnoses on their decisions. Results Nearly all (99.6%) patients, regardless of gender, age, and presence of oncological diagnosis, consented to the storage of their biological material, 98.4% of patients, regardless of gender, age, and presence of oncological diagnosis, wanted to be included in international databases in a pseudo-anonymised form, 98.8% of patients, irrespective of gender, age, and presence of oncological diagnosis, allowed blood relatives to see their results, and 98.4% of patients, irrespective of gender, age and presence of oncological diagnosis, wanted to know whether secondary findings were detected when genetic analysis of their biological material was performed. Men are, on average, more likely to consent but the difference between genders is not statistically significant. Patients without oncological disease were more likely to agree to be included in international databases than patients with a confirmed oncological diagnosis. Conclusions Our results show that the vast majority of patients were in favour of the options they were offered. Most importantly, the majority of them allow their genetic test results be revealed to their blood relatives when needed and would participate in international databases. Research in rare diseases, including rare cancer genetic predisposition syndromes, is crucial for optimal diagnostic, prevention and treatment options for patients with rare genetic disorders. The results are also important for refining the approach to pre-and post-test cancer genetic counselling.
Ključne besede:informed consent, genetic counselling, genetic testing
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Poslano v recenzijo:15.11.2024
Datum sprejetja članka:13.02.2025
Datum objave:21.02.2025
Založnik:BioMed Central Ltd (Springer Nature)
Leto izida:2025
Št. strani:9 str.
Številčenje:Vol. 23
PID:20.500.12556/DiRROS-23999 Novo okno
UDK:616-07
ISSN pri članku:1897-4287
DOI:10.1186/s13053-025-00309-8 Novo okno
COBISS.SI-ID:227017219 Novo okno
Avtorske pravice:by Authors
Opomba:Nasl. z nasl. zaslona; Opis vira z dne 8. 10. 2025;
Datum objave v DiRROS:19.11.2025
Število ogledov:116
Število prenosov:52
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Hereditary Cancer in Clinical Practice
Skrajšan naslov:Hered. Cancer Clin. Pract.
Založnik:Termedia
ISSN:1897-4287
COBISS.SI-ID:523112217 Novo okno

Gradivo je financirano iz projekta

Financer:ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:P3-0289-2019
Naslov:Značilnosti malignih neoplazem, pomembne za diagnozo ter napoved poteka bolezni in izida zdravljenja

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:informirano soglasje, genetsko svetovanje, genetsko testiranje


Nazaj